A Novel Herbal Medicine for Dyslipidemia: Assessments in Experimental Models

Table 3

Effect of GANMO on lipid levels in cholesterol-induced dyslipidemia after 4 weeks of treatment.

Groups/treatment on 4^th week	n	TG ( ± SD)	TC ( ± SD)	HDL-C ( ± SD)	LDL-C ( ± SD)
Control group	10	0.52 ± 0.10	2.06 ± 0.14	0.92 ± 0.25	0.90 ± 0.24
Model group	10	0.83 ± 0.09	3.55 ± 0.57	1.38 ± 0.38	1.79 ± 0.59
Atorvastatin (10 mg/kg)	10	0.75 ± 0.25	2.93 ± 0.53^Δ	1.72 ± 0.20^Δ	0.87 ± 0.27^ΔΔΔ
GANMO (15.1 g/kg)	10	0.81 ± 0.16	2.82 ± 0.55^ΔΔ	1.25 ± 0.19	1.20 ± 0.46^Δ
GANMO (45.3 g/kg)	10	0.91 ± 0.19	3.01 ± 0.39^Δ	1.45 ± 0.46	1.15 ± 0.38^ΔΔ

Note: statistical analysis was done with t test and ANOVA test, and was considered to be statistically significant; : and compared with control group; ^{Δ, ΔΔ, ΔΔΔ}: , , and compared with the model group.